BRISTOL MYERS SQUIBB CO Form 8-K December 16, 2004

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 8-K

#### **CURRENT REPORT**

#### Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 14, 2004

#### **BRISTOL-MYERS SQUIBB COMPANY**

(Exact Name of Registrant as Specified in its Charter)

Delaware	1-1136	22-079-0350
(State or Other	(Commission File	(IRS Employer
Jurisdiction of	Number)	Identification
Incorporation)		Number)

345 Park Avenue New York, NY, 10154 (Address of Principal Executive Office)

Registrant s telephone number, including area code: (212) 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# **TABLE OF CONTENTS**

<u>Item 8.01. Other Events.</u>
<u>Item 9.01 Financial Statement and Exhibits SIGNATURES</u>

EX-99.1:PRESS RELEASE

#### **Table of Contents**

#### Item 8.01. Other Events.

On December 14, 2004, Bristol-Myers Squibb Company announced it signed a definitive agreement to sell its Oncology Therapeutics Network (OTN) unit to One Equity Partners LLC. The transaction is expected to be completed during the first quarter of 2005, pending certain regulatory approvals. A copy of the press release is attached to this report as Exhibit 99.1.

#### **Item 9.01 Financial Statements and Exhibits**

#### (c) Exhibits

99.1 Press Release, dated December 14, 2004, of Bristol-Myers Squibb Company.

#### **Table of Contents**

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Bristol-Myers Squibb Company

Date: December 16, 2004

By: /s/ Sandra Leung

Name: Sandra Leung Title: Secretary

#### **EXHIBIT INDEX**

Exhibit No. Description

99.1 Press Release, dated December 14, 2004, of Bristol-Myers Squibb Company.